Skip to main content

Table 1 Patient demographics and pathological evaluation

From: A greater lymph node yield is required during pathological examination in microsatellite instability-high gastric cancer

 

MSI-H GC

MSS GC

 

n = 185 (10.5%)

n = 1572 (89.5%)

p value

Sex, n (%)

  

< 0.001

 Male

103 (55.7)

1088 (69.2)

 

 Female

82 (44.3)

484 (30.8)

 

Age [y], median (quartile)

67 (60–73)

62 (54–69)

< 0.001

Tumor location, n (%)

  

< 0.001

 Antrum and pylorus

125 (67.6)

713 (45.4)

 

 Angular

23 (12.4)

184 (11.7)

 

 Corpus

22 (11.9)

366 (23.3)

 

 Fundus and cardia

15 (8.1)

309 (19.7)

 

Neoadjuvant therapy, n (%)

  

0.166

 No

165 (89.2)

1343 (85.4)

 

 Yes

20 (10.8)

229 (14.6)

 

Extent of lymphadenectomy

  

0.499

 D1+ lymphadenectomy

22 (11.9)

221 (14.1)

 

 D2 lymphadenectomy

163 (88.1)

1351 (85.9)

 

Tumor size [cm], median (quartile)

4 (2–6.5)

3 (2–4.8)

< 0.001

Pathology type, n (%)

  

< 0.001

 Well-differentiated adenocarcinoma

66 (35.7)

425 (27.0)

 

 Moderately and poor-differentiated adenocarcinoma

67 (36.2)

554 (35.2)

 

 Mucinous adenocarcinoma

31 (16.8)

100 (6.4)

 

 Signet ring cell carcinoma

21 (11.4)

493 (31.4)

 

Tumor stage, n (%)

  

0.205

 Early GC

47 (25.4)

470 (29.9)

 

 Advanced GC

138 (74.6)

1102 (70.1)

 

T stage, n (%)

  

0.600

 Tis and T1

47 (25.4)

470 (29.9)

 

 T2

36 (19.5)

236 (15.0)

 

 T3

34 (18.4)

167 (10.6)

 

 T4

68 (36.8)

699 (44.5)

 

Lymphovascular emboli, n (%)

  

0.002

 No

97 (52.4)

1008 (64.1)

 

 Yes

88 (47.6)

564 (35.9)

 

Perineural invasion, n (%)

  

< 0.001

 No

138 (74.6)

955 (60.8)

 

 Yes

47 (25.4)

617 (39.2)

 

Tumor deposit, n (%)

  

0.009

 No

180 (97.3)

1445 (91.9)

 

 Yes

5 (2.7)

127 (8.1)

 

PLNC, median (quartile)

0 (0–3)

2 (0–7)

< 0.001

NLNC, median (quartile)

27 (21–35)

23 (16–32)

< 0.001

N stage, n (%)

  

< 0.001

 N0

95 (51.4)

630 (40.1)

 

 N1

33 (17.8)

239 (15.2)

 

 N2

30 (16.2)

276 (17.6)

 

 N3a

19 (10.3)

259 (16.5)

 

 N3b

8 (4.3)

168 (10.7)

 

M stage, n (%)

  

0.002

 M0

185 (100.0)

1495 (95.1)

 

 M1

0 (0.0)

77 (4.9)

 

AJCC stage, n (%)

  

0.005

 I

68 (36.8)

545 (38.9)

 

 II

57 (30.8)

298 (19.1)

 

 III

60 (32.4)

652 (40.4)

 

 IV

0 (0.0)

77 (4.9)

 
  1. MSI microsatellite instability
  2. MSS microsatellite stability
  3. GC gastric cancer
  4. PLNC positive lymph node count
  5. NLNC negative lymph node count
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us